STOCK TITAN
  1. Home
  2. Sec-filings
  3. STOK
  4. [Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

STOK Form 4: Director sold 42,461 shares under 10b5-1 plan

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Director Edward M. Kaye reported the sale of 42,461 shares of Stoke Therapeutics common stock on 10/03/2025 under a pre-existing Rule 10b5-1 trading plan. The filing shows a weighted-average sale price of $25.0867 (individual trades ranged from $25.00 to $25.30), leaving the reporting person with 49,124 shares beneficially owned after the transactions. The schedule was signed by an attorney-in-fact on 10/07/2025.

Positive

  • Transaction executed under a Rule 10b5-1 plan, indicating trades were pre-planned (adopted 12/30/2024).
  • Complete pricing disclosure with weighted-average price and range ($25.0867, range $25.00-$25.30), enabling transparency.

Negative

  • Insider reduced holdings by 42,461 shares, lowering beneficial ownership to 49,124 shares.
  • Concentration change may be perceived negatively by investors who monitor insider ownership trends.

Insights

TL;DR: Director executed a pre-planned sale under a 10b5-1 plan, reducing direct holdings.

The sale of 42,461 shares at a weighted-average price of $25.0867 was executed pursuant to a Rule 10b5-1 trading plan adopted on 12/30/2024, which provides an affirmative defense against insider trading claims when properly structured and reported.

This transaction lowers the director's direct stake to 49,124 shares; the principal governance implication is a modest reduction in insider ownership. Monitor subsequent Section 16 filings for additional plan-based trades or changes in beneficial ownership within the next reporting period.

Insider Kaye Edward M. MD
Role Director
Sold 42,461 shs ($1.07M)
Type Security Shares Price Value
Sale Common Stock 42,461 $25.0867 $1.07M
Holdings After Transaction: Common Stock — 49,124 shares (Direct)
Footnotes (1)
  1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kaye Edward M. MD
(Last) (First) (Middle)
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE
(Street)
BEDFORD MA 01730
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/03/2025 S(1) 42,461 D $25.0867(2) 49,124 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Jonathan Allan, Attorney-in-Fact 10/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Stoke Therapeutics (STOK) director Edward M. Kaye sell on 10/03/2025?

The director sold 42,461 shares of common stock at a weighted-average price of $25.0867, with trade prices ranging from $25.00 to $25.30.

Was the sale by the STOK director part of a Rule 10b5-1 plan?

Yes. The filing states the transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on 12/30/2024.

How many STOK shares does the reporting person own after the sale?

After the reported transaction, the reporting person beneficially owned 49,124 shares.

Where can I find the exact sale price details for the STOK Form 4?

The Form 4 lists a weighted-average price of $25.0867 and notes individual sale prices ranged from $25.00 to $25.30.

Who signed the Form 4 for the STOK insider filing?

The filing was signed by Jonathan Allan, Attorney-in-Fact on 10/07/2025.